17β-hydroxysteroid dehydrogenase inhibitors

Minerva Endocrinologica

Volumn 35, Issue 2, 2010, Pages 87-108

  Day, J M ^a   Tutill, H J ^a   Purohit, A ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

17 hydroxysteroid dehydrogenase; Enzymes; Steroids

Indexed keywords

16ALPHA BROMOACETOXYESTRADIOL 3 METHYL ETHER; 2 ETHYL 16BETA PYRIDYLMETHYLAMIDOMETHYLESTRONE; 3 CHLOROACETYLPYRIDINE ADENINE DINUCLEOTIDE; 667 COUMATE; 6BETA BROMOACETOXYPROGESTERONE; ADENINE NUCLEOTIDE DERIVATIVE; APIGENIN; BICALUTAMIDE; CETRORELIX; CINNAMIC ACID DERIVATIVE; CURCUMIN; EM 1745; ENZYME INHIBITOR; EQUILIN; ESTRADIOL DERIVATIVE; ESTRONE DERIVATIVE; FINASTERIDE; GOSERELIN; GOSSYPOL; LETROZOLE; PROGESTERONE DERIVATIVE; PYRIDINE DERIVATIVE; STERYL SULFATASE; STX 1040; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; TESTOSTERONE 17BETA DEHYDROGENASE 3; TESTOSTERONE 17BETA DEHYDROGENASE 5; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; HYDROXYSTEROID DEHYDROGENASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STEROID METABOLISM; STRUCTURE ACTIVITY RELATION; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; MALE; PROSTATE TUMOR; TREATMENT OUTCOME;

17-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENDOMETRIOSIS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77957695010     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (190)

1. Peltoketo H, Isomaa V, Poutanen M, Vihko R. Expression and regulation of 17β-hydroxysteroid dehydrogenase type 1. J Endocrinol 1996;150:S21-30.
2. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa W, Vihko RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 1996;314:839-45.
3. Lin SX, Shi R, Qiu W, Azzi A, Zhu DW, Dabbagh HA et al. Structural basis of the multispecificity demonstrated by 17β-hydroxysteroid dehydrogenase types 1 and 5. Mol Cell Endocrinol 2006;248:38-46.
4. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities:oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581-7. (Pubitemid 26019342)
5. Pelletier G, Luu-The V, Tẽtu B, Labrie F. Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 1999;47:731-7.
6. Ji Q, Aoyama C, Chen PK, Stolz A, Liu P. Localization and altered expression of AKR1C family members in human ovarian tissues. Mol Cell Probes 2005;19:261-6.
7. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M et al. Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 1998;124:940-6.
8. Komoto J, Yamada T, Watanabe K, Takusagawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 2004;43:2188-98.
9. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM et al. Aldo-keto reductase (AKR) 1C3.role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006;248:182-91.
10. Day JM, Tutill HJ, Purohit A, Reed MJ. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 2008;15:665-92.
11. Breitling R, Marijanoviç Z, Peroviç D, Adamski J. Evolution of 17β-HSD type 4, a multifunctional protein of β-oxidation. Mol Cell Endocrinol 2001;171:205-10.
12. Pletnev VZ, Duax WL. Rational proteomics IV:modeling the primary function of the mammalian 17β-hydroxysteroid dehydrogenase type 8. J Steroid Biochem Mol Biol 2005;94:327-35.
13. Yang SY, He XY, Schulz H. Multiple functions of type 10 17β-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 2005;16:167-75. (Pubitemid 40603096)
14. Nagasaki S, Suzuki T, Miki Y, Akahira J, Kitada K, Ishida T et al. 17β-hydroxysteroid dehydrogenase type 12 in human breast carcinoma:a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 2009;69:1392-9.
15. Rantakari P, Lagerbohm H, Kaimainen M, Suomela JP, Strauss L, Sainio K et al. Hydroxysteroid (17,) dehydrogenase 12 is essential for mouse organogenesis and embryonic survival. Endocrinology 2010;151:1893-901.
16. Jokela H, Rantakari P, Lamminen T, Strauss L, Ola R, Mutka AL et al. Hydroxysteroid (17,) dehydrogenase 7 activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal survival and cardiovascular differentiation in early mouse embryos. Endocrinology 2010;151:1884-92.
17. Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207-21. (Pubitemid 351611954)
18. Stanway SJ, Purohit A, Woo LW, Sufi S, Vigushin D, Ward R et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients:the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92.
19. Purohit A, Woo LW, Chander SK, Newman SP, Ireson C, Ho Y et al. Steroid sulphatase inhibitors for breast cancer therapy. J Steroid Biochem Mol Biol 2003;86:423-32. (Pubitemid 37412580)
20. Stanway SJ, Delavault P, Purohit A, Woo LWL, Thurieau C, Potter BVL et al. Steroid sulfatase:a new target for the endocrine therapy of breast cancer. Oncologist 2007;12:370-4.
21. Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM et al. The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 2006;248:199-203.
22. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinomas correlation to clinicopathological parameters. Br J Cancer 2000;82:518-23.
23. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001;94:685-9. (Pubitemid 33035688)
24. Gunnarsson C, Hellqvist E, Stål O. 17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 2005;92:547-52.
25. Salhab M, Reed MJ, Al Sarakbi W, Jiang WG, Mokbel K. The role of aromatase and 17β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Tr 2006;99:155-62.
26. Vihko P, Herrala A, Härkönen P, Isomaa V, Kaija H, Kurkela R et al. Control of cell proliferation by steroids:the role of 17HSDs. Mol Cell Endocrinol 2006;248:141-8.
27. Reed MJ, Purohit A. Pharmacology of inhibition of estrogen metabolising enzymes. In: Oettel M, Schillinger E, editors. Handbook of experimental pharmacology. Vol 135/II: Estrogens and antiestrogens. Berlin: Springer Verlag; 1999. p. 231-45.
28. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 2006;13:129-36.
29. Källström AC, Salme R, Rydén L, Nordenskjöld B, Jönsson PE, Stål O. 17β-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur J Cancer 2010;46:892-900.
30. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E et al. Progesterone resistance in endometriosis:Link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
31. Matsuzaki S, Canis M, Pouly JL, Botchorishvili R, Déchelotte PJ, Mage G. Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis. Fertil Steril 2006;86:548-53.
32. Carneiro MM, Morsch DM, Camargos AF, Spritzer PM, Reis FM. Expression of 17β-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis. Gynecol Endocrinol 2007;23:188-92.
33. Smuc T, Pucelj MR, Sinkovec J, Husen B, Thole H, Rizner TL. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecol Endocrinol 2007;23:105-11.
34. Aghajanova L, Hamilton A, Kwintkiewicz J, Vo KC, Giudice LC. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. Biol Reprod 2009;80:105-14.
35. Dassen H, Punyadeera C, Kamps R, Delvoux B, Van Langendonckt A, Donnez J et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Human Reproduction 2007;22:3148-58. (Pubitemid 351696776)
36. Sherman ME. Theories of endometrial carcinogenesis:a multidisciplinary approach. Mod Pathol 2000;13:295-308.
37. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:213-9.
38. Tsuchiya M, Nakao H, Katoh T, Sasaki H, Hiroshima M, Tanaka T et al. Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19. Hum Reprod 2005;20:974-8.
39. Saloniemi T, Lamminen T, Huhtinen K, Welsh M, Saunders P, Kujari H et al. Activation of androgens by hydroxysteroid (17,) dehydrogenase 1 in vivo as a cause of prenatal masculinization and ovarian benign serous cystadenomas. Mol Endocrinol 2007;21:2627-36.
40. Zhu DW, Lee X, Breton R, Ghosh D, Pangborn W, Duax WL et al. Crystallization and preliminary X-ray diffraction analysis of the complex of human placental 17β-hydroxysteroid dehydrogenase with NADP+. J Mol Biol 1993;234:242-4. (Pubitemid 23337979)
41. Zhu DW, Lee X, Labrie F, Lin SX. Crystal growth of human estrogenic 17β-hydroxysteroid dehydrogenase. Acta Crystallogr D Biol Crystallogr 1994;50:550-5.
42. Duax WL, Ghosh D, Pletnev V. Steroid dehydrogenase structures, mechanism of action, and disease. Vitam Horm 2000;58:121-48.
43. Azzi A, Rehse PH, Zhu DW, Campbell RL, Labrie F, Lin SX. Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol. Nat Struct Biol 1996;3:665-8.
44. + identifies two principal targets for the design of inhibitors. Structure 1996;4:905-15.
45. Ghosh D, Pletnev VZ, Zhu DW, Wawrzak Z, Duax WL, Pangborn W et al. Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 1995;3:503-13.
46. Puranen T, Poutanen M, Ghosh D, Vihko P, Vihko R. Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 1997;11:77-86. (Pubitemid 27021256)
47. Gangloff A, Shi R, Nahoum V, Lin SX. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17β-hydroxysteroid dehydrogenase. FASEB J 2003;17:274-6.
48. Shi R, Lin SX. Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J Biol Chem 2004;279:16778-85.
49. Zhorov BS, Lin SX. Monte Carlo-Minimized energy profile of estradiol in the ligand-binding tunnel of 17β-hydroxysteroid dehydrogenase:atomic mechanisms of steroid recognition. Proteins 2000;38:414-27.
50. Betz G. Reaction mechanism of 17β-estradiol dehydrogenase determined by equilibrium rate exchange. J Biol Chem 1971;246:2063-8.
51. Karkola S, Alho-Richmond S, Wahala K. Pharmacophore modelling of 17β-HSD1 enzyme based on active inhibitors and enzyme structure. Mol Cell Endocrinol. 2009;301:225-8.
52. Karkola S, Lilienkampf A, Wähälä K. A 3D QSAR model of 17β-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking. ChemMedChem 2008;3:461-72.
53. Schuster D, Nashev LG, Kirchmair J, Laggner C, Wolber G, Langer T et al. Discovery of nonsteroidal 17β-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem 2008;51:4188-99.
54. Blomquist CH, Lindemann NJ, Hakanson EY. Inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD) activities of human placenta by steroids and non-steroidal hormone agonists and antagonists. Steroids 1984;43:571-86.
55. Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D. Structure of the ternary complex of human 17β-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 1999;96:840-5.
56. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G. Aromatase and 17β-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett 1998;133:101-6. (Pubitemid 29069117)
57. Brozic P, Kocbek P, Sova M, Kristl J, Martens S, Adamski J et al. Flavonoids and cinnamic acid derivatives as inhibitors of 17β- hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2009;301:229-34.
58. Makelä S, Poutanen M, Kostian ML, Lehtimäki N, Strauss L, Santti R et al. Inhibition of 17β-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998;217:310-6.
59. Hoffrén AM, Murray CM, Hoffmann RD. Structure-based focusing using pharmacophores derived from the active site of 17β-hydroxysteroid dehydrogenase. Curr Pharm Des 2001;7:547-66.
60. Han Q, Lin SX. The study of crystallization of estrogenic 17β-hydroxysteroid dehydrogenase with DHEA and DHT at elevated temperature. Biochem Biophys Res Comm 2000;277:100-6.
61. Owen CP, Ahmed S. The derivation of a potential transition state for the reduction reaction catalysed by 17β-hydroxysteroid dehydrogenase - an approximate representation of its active site for use in drug design and discovery. Biochem Biophys Res Comm 2004;318:131-4. (Pubitemid 38526255)
62. Alho-Richmond S, Lilienkampf A, Wähälä K Active site analysis of 17β-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT. Mol Cell Endocrinol 2006;248:208-13.
63. BroÏiã P, Golob B, Gomboc N, Rizner TL, Gobec S. Cinnamic acids as new inhibitors of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol Cell Endocrinol 2006;248:233-5.
64. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G. Chalcones are potent inhibitors of aromatase and 17β-hydroxysteroid dehydrogenase activities. Life Sci 2001;68:751-61.
65. Arlt W, Neogi P, Gross C, Miller WL. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3β-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARγ agonist activity. J Mol Endocrinol 2004;32:425-36.
66. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J 2006;53:7-20.
67. Turner JV, Agatonovic-Kustrin S, Glass BD. Molecular aspects of phytoestrogen selective binding at estrogen receptors. J Pharm Sci 2007;96:1879-85. (Pubitemid 47280089)
68. Labrie C, Martel C Dufour JM, Lévesque C, Mérand Y, Labrie F. Novel compounds inhibit estrogen formation and action. Cancer Res 1992;52:610-5.
69. Tremblay MR, Poirier D. Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity:chemical synthesis and biological evaluation. J Steroid Biochem Mol Biol 1998;66:179-91.
70. Poirier D, Dionne P, Auger S. A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 1998;64:83-90. (Pubitemid 28132850)
71. Sam KM, Boivin RP, Tremblay MR, Auger S, Poirier D. C16 and C17 Derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1:chemical synthesis and structure-activity relationships. Drug Des Discov 1998;15:157-80. (Pubitemid 28301999)
72. Deluca D, Möller G, Rosinus A, Elger W, Hillisch A, Adamski J. Inhibitory effects of fluorine-substituted estrogens on the activity of 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:218-24.
73. Möller G, Deluca D, Gege C, Rosinus A, Kowalik D, Peters O et al. Structure-based design, synthesis and in vitro characterization of potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone. Bioorg Med Chem Lett 2009;19:6740-4.
74. Tremblay MR, Boivin RP, Luu-The V, Poirier D. Inhibitors of type 1 17β-hydroxysteroid dehydrogenase with reduced estrogenic activity:modifications of the positions 3 and 6 of estradiol. J Enzyme Inhib Med Chem 2005;20:153-63. (Pubitemid 40645506)
75. Fournier D, Poirier D, Mazumdar M, Lin SX. Design and synthesis of bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase:overview and perspectives. Eur J Med Chem 2008;43:2298-306.
76. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, Tremblay MR et al. A concerted, rational design of type 1 17β-hydroxysteroid dehydrogenase inhibitors:estradiol-adenosine hybrids with high affinity. FASEB J 2002;16:1829-31.
77. Bérubé M, Poirier D. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17β-hydroxysteroid dehydrogenase type 1. J Enzyme Inhib Med Chem 2009;24:832-43.
78. Poirier D, Boivin RP, Tremblay MR, Bérubé M, Qiu W, Lin SX. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase. J Med Chem 2005;48:8134-47.
79. Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ et al. E-ring modified steroids as novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J Med Chem 2005;48:5749-70. (Pubitemid 41298348)
80. Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ, Purohit A et al. Novel, potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006;248:204-7.
81. Messinger J, Husen B, Koskimies P, Hirvelä L, Kallio L, Saarenketo P et al. Estrone C15 derivatives - a new class of 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Mol Cell Endocrinol 2009;301:216-24.
82. Lawrence HR, Vicker N, Allan GM, Smith A, Mahon MF, Tutill HJ et al. Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 2005;48:2759-62.
83. Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, Vicker N et al. Modification of estrone at the 6, 16, and 17 positions:novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J Med Chem 2006;49:1325-45.
84. Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ et al. Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids:inhibitors of 17β-hydroxysteroid dehydrogenase type 1. ChemMedChem 2006;1:464-81.
85. Allan GM, Vicker N, Lawrence H, Tutill HJ, Purohit A, Day JM et al. Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1:Templates for design. Bioorg Med Chem 2008;16:4438-56.
86. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L et al. Design, synthesis, and biological evaluation of (hydroxyphenyl)-naphthalene and -quinoline derivatives:potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 2008;51:2158-69.
87. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, Klein T et al. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and - benzenes:influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity. J Med Chem 2009;52:6724-43.
88. Oster A, Klein T, Werth R, Kruchten P, Bey E, Negri M et al. Novel estrone mimetics with high 17β-HSD1 inhibitory activity. Bioorg Med Chem 2010;18:3494-505.
89. Day JM, Tutill HJ, Newman SP, Purohit A, Lawrence HR, Vicker N et al. 17β-Hydroxysteroid dehydrogenase Type 1 and Type 2:Association between mRNA expression and activity in cell lines. Mol Cell Endocrinol 2006;248:246-9.
90. Day JM, Foster PA, Chander SK, Tutill HJ, Parsons MFC, Allan GM et al. Inhibition of estrone-dependent tumor growth in vivo by the 17β-HSD1 inhibitor, 2-ethyl-16β-m-pyridylmethylamidomethyl-estrone (2-EtE1-F). Breast Cancer Res Tr 2006;100:S197.
91. + breast cancer cell proliferation induced by estrone. Bioorg Med Chem 2008;16:1849-60. (Pubitemid 351226579)
92. Day JM, Foster PA, Tutill HJ, Parsons MFC, Newman SP, Chander SK et al. 17β-Hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 2008;122:1931-40.
93. Nokelainen P, Puranen T, Peltoketo H, Orava M, Vihko P, Vihko R. Molecular cloning of mouse 17β-hydroxysteroid dehydrogenase type 1 and characterization of enzyme activity. Eur J Biochem 1996;236:482-90. (Pubitemid 26098832)
94. Ghersevich S, Nokelainen P, Poutanen M, Orava M, Autio-Harmainen H, Rajaniemi H et al. Rat 17β-hydroxysteroid dehydrogenase type 1:primary structure and regulation of enzyme expression in rat ovary by diethylstilbestrol and gonadotropins in vivo. Endocrinology 1994;135:1477-87.
95. Peltoketo H, Luu-The V, Simard J, Adamski J. 17β-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family;nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 1999;23:1-11.
96. Pelletier G, Luu-The V, Li S, Ren L, Labrie F. Localization of 17β-hydroxysteroid dehydrogenase type 1 mRNA in mouse tissues. J Mol Endocrinol 2004;33:459-65. (Pubitemid 39429569)
97. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5. (Pubitemid 24313482)
98. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H. Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 2006;248:109-13.
99. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH, Poutanen M. Human hydroxysteroid (17-,) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006;147:5333-9.
100. Messinger J, Hirvelä L, Husen B, Kangas L, Koskimies P, Pentikäinen O et al. New inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006;248:192-8.
101. Lamminen T, Saloniemi T, Huhtinen K, Koskimies P, Messinger J, Husen B et al. in vivo mouse model for analysis of hydroxysteroid (17,) dehydrogenase , inhibitors. Mol Cell Endocrinol 2009;301:158-62.
102. Saloniemi T, Järvensivu P, Koskimies P, Jokela H, Lamminen T, Ghaem-Maghami S et al. Novel hydroxysteroid (17,) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. Am J Pathol 2010;176:1443-51.
103. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancenlocking up the molecular escape routes. Clin Cancer Res 2009;15:3251-5.
104. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71.
105. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010;70:3309-19.
106. Rau KM, Rang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005;12:511-32.
107. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.
108. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestesterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
109. Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008;295:115-20.
110. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68: 6407-15.
111. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-7.
112. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y et al. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-6. (Pubitemid 350239034)
113. Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB et al. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nat Genet 1994;7:34-9.
114. Andersson S, Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids 1997;62:143-7.
115. Lee YS, Kirk JM, Stanhope RG, Johnston DI, Harland S, Auchus RJ et al. Phenorypic variability in 17β-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls. Clin Endocrinol 2007;67:20-8.
116. Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA. 17β-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite. Fertil Steril 2008;89:228.e13-7.
117. Andersson S, Geissler WM, Wu L, Davis DL, Grumbach MM, New MI et al. Molecular genetics and pathophysiology of 17β-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996;81:130-6.
118. Koh E, Noda T, Kanaya J, Namiki M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 2002;53:154-9.
119. Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F, Chiliemi G et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 2007;25:491-7. (Pubitemid 47222914)
120. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ et al. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009;15:4815-22.
121. Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002;53:65-8.
122. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express steroidogenic 17β-hydroxysteroid dehydrogenases:Distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost 2005;94:412-21.
123. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H et al. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily:functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochemical J 2000;351:67-77.
124. Penning TM, Jin Y, Steckelbroeck S, RiÏner TL, Lewis M. Structure-function of human 3α-hydroxysteroid dehydrogenases:genes and proteins. Mol Cell Endocrinol 2004;215:63-72. (Pubitemid 38337424)
125. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-74.
126. Sharma KK, Lindqvist A, Zhou XJ, Auchus RJ, Penning TM, Andersson S. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol Cell Endocrinol 2006;248:79-86.
127. Wang S, Yang Q, Fung KM, Lin HK. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol 2008;289:60-6.
128. Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal antiinflammatory drugs. Cancer Res 2003;63:505-12.
129. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B et al. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-80.
130. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 2006;147:5806-16. (Pubitemid 44833497)
131. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005;12:101-7.
132. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008;61:448-54.
133. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66;2815-25.
134. Roberts RO, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunningham JM et al. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. Prostate 2006;66:392-404.
135. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001;26:11-9.
136. Amin SA, Huang CC, Reierstad S, Lin Z, Arbieva Z, Wiley E et al. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Mol Cell Endocrinol 2006;253:44-55. (Pubitemid 43946568)
137. Vihko P, Herrala A, Härkönen P, Isomaa V, Kaija H, Kurkela R et al. Enzymes as modulators in malignant transformation. J Steroid Biochem Mol Biol 2005:93:277-83.
138. Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP et al. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol 2009;3:147-55.
139. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ et al. Peroxisomal branched chain fatty acid β-oxidation pathway is upregulated in prostate cancer. Prostate 2005;63:316-23.
140. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006;103:10991-6.
141. Rasiah KK, Gardiner-Garden M, Padilla EJD, Möller G, Kench JG, Alles MC et al. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 2009;301:89-96.
142. McKeever BM, Hawkins BK, Geissler WM, Wu L, Sheridan RP, Mosley RT et al. Amino acid substitution of arginine 80 in 17β-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics. Biochim Biophys Acta 2002;1601:29-37. (Pubitemid 38234528)
143. Pittaway DE. Inhibition of testosterone synthesis in the canine testis in vitro. Contraception 1983;27:431-6.
144. Lombardo ME, Hakky SI, Hudson PB. In vitro studies on the inhibition of testosterone synthesis in the human testis by atamestane. J Steroid Biochem Mol Biol 1993;44:287-90.
145. Le Lain R, Nicholls PJ, Smith HJ, Maharlouie FH. Inhibitors of human and rat testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD) as potential agents for prostatic cancer. J Enzyme Inhib 2001;16:35-45. (Pubitemid 32331646)
146. Ohno S, Honda Y, Nakajima Y, Nakajin S. Sequence of pig 17β-hydroxysteroid dehydrogenase Type3 cDNA and its expression in mammalian cells. J Steroid Biochem Mol Biol 2006;101:145-50.
147. Tchédam Ngatcha B, Luu-The V, Poirier D. Androsterone derivatives substituted at position 16:chemical synthesis, inhibition of type 3 17β-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells. J Enzyme Inhib Med Chem 2002;17:155-65.
148. Tchédam Ngatcha B, Luu-The V, Poirier D. Androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase. Bioorg Med Chem Lett 2000;10:2533-6.
149. Tchédam Ngatcha B, Luu-The V, Labrie F, Poirier D. Androsterone 3α-ether-3β-substituted and androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: Chemical synthesis and structure-activity relationship. J Med Chem 2005;48:5257-68. (Pubitemid 41113912)
150. Maltais R, Luu-The V, Poirier D. Parallel solid-phase synthesis of 3β-peptido-3α-hydroxy-5α-androstan-17-one derivatives for inhibition of type 3 17β-hydroxysteroid dehydrogenase. Bioorg Med Chem 2001;9:3101-11.
151. Maltais R, Luu-The V, Poirier D. Synthesis and optimization of a new family of type 3 17β-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry. J Med Chem 2002;45.640-53. (Pubitemid 34145710)
152. Spires TE, Fink BE, Kick EK, You D, Rizzo CA, Takenaka I et al. Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3). Prostate 2005;65:159-70. (Pubitemid 41362283)
153. Fink BE, Gavai AV, Tokarski JS, Goyal B, Misra R, Xiao HY et al. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg Med Chem Lett 2006;16:1532-6. (Pubitemid 43197517)
154. Lota RK, Olusanjo MS, Dhanani S, Owen CP, Ahmed S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17β-hydroxysteroid dehydrogenase (17β-HSD3). J Steroid Biochem Mol Biol 2008;111:128-37.
155. Bérubé M, Poirier D. Chemical synthesis and in vitro biological evaluation of a phosphorylared bisubstrate inhibitor of type 3 17β-hydroxysteroid dehydrogenase. J Enzyme Inhib Med Chem 2007;22:201-11. (Pubitemid 46592509)
156. Hu GX, Zhou HY, Li XW, Chen BB, Xiao YC, Lian QQ et al. The (+)- and (-)-gossypols potently inhibit both 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 in human and rat testes. J Steroid Biochem Mol Biol 2009;115:14-9.
157. Hu GX, Liang G, Chu Y, Li X, Lian QQ, Lin H et al. Curcumin derivatives inhibit testicular 17β-hydroxysteroid dehydrogenase 3. Bioorg Med Chem Lett 2010;20:2549-51.
158. Le Lain R, Barrell KJ, Saeed GS, Nicholls PJ, Simons C, Kirby A et al. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD type 3):further studies with tamoxifen on the rat testes microsomal enzyme. J Enzyme Inhib Med Chem 2002;17;93-100.
159. Harada K, Kubo H, Tomigahara Y, Nishioka K, Takahashi J, Momose M et al. Coumarins as novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. Bioorg Med Chem Lett 2010;20:272-5.
160. Ohno S, Nakajima Y, Nakajin S. Triphenyltin and tributyltin inhibit pig testicular 17β-hydroxysteroid dehydrogenase activity and suppress testicular testosterone biosynthesis. Steroids 2005;70:645-51.
161. Nashev LG, Schuster D, Laggner C, Sodha S, Langer T, Wolber G et al. The UV-filter benzophenone-1 inhibits 17β-hydroxysteroid dehydrogenase type 3:Virtual screening as a strategy to identify potential endocrine disrupting chemicals. Biochem Pharmacol 2010;79:1189-99.
162. Minesita T, Yamaguchi K. An androgen-dependent mouse mammary tumor. Cancer Res 1965;25:1168-75.
163. Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM et al. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Mol Cell Endocrinol 2009;301:251-8.
164. Vicker N, Sharland CM, Heaton WB, Gonzalez AM, Bailey HV, Smith A et al. The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Mol Cell Endocrinol 2009;301:259-65.
165. Novotna R, Wsol V, Xiong G, Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett 2008;181:1-6.
166. Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009;19:477-88.
167. Qiu W, Zhou M, Labrie F, Lin SX. Crystal structures of the multispecific 17β-hydroxysteroid dehydrogenase type 5:critical androgen regulation in human peripheral tissues. Mol Endocrinol 2004;18:1798-807. (Pubitemid 38859585)
168. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA. Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 2004;64:1802-10.
169. Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F. Prostaglandin F2α formation from prostaglandin H2 by prostaglandin F synthase (PGFS):Crystal structure of PGFS containing Bimatoprost. Biochemistry 2006;45:1987-96. (Pubitemid 43271298)
170. Qiu W, Zhou M, Mazumdar M, Azzi A, Ghanmi D, Luu-The V et al. Structure-based inhibitor design for an enzyme that binds different steroids:a potent inhibitor for human type 5 17β-hydroxysteroid dehydrogenase. J Biol Chem 2007;282:8368-79. (Pubitemid 47093565)
171. Krazeisen A, Breitling R, Möller G, Adamski J. Phytoestrogens inhibit human 17β-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol 2001;171:151-62.
172. Skarydová L, Zivná L, Xiong G, Maser E, Wsól V. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact 2009;178:138-44.
173. Davies NJ, Hayden RE, Simpson PJ, Birtwistle J, Mayer K, Ride JP et al. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Cancer Res 2009;69:4769-75.
174. Stefane B, Brozic P, Vehovc M, Rizner TL, Gobec S. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem 2009;44:2563-71.
175. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y et al. Substrate specificity of human 3(20)α-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull 2002;25:441-5.
176. Bydal P, Luu-The V, Labrie F, Poirier D. Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5:chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem 2009;44:632-44.
177. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, Penning TM. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms:potential anti-neoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 2005;67:60-8.
178. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75:484-93. (Pubitemid 350298472)
179. Gobec S, BroÏiã P, RiÏner TL. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldoketo reductase AKR1C3:New lead compounds for the development of anticancer agents. Bioorg Med Chem Lett 2005;15:5170-75. (Pubitemid 41463641)
180. Byrns MC, Penning TM. Type 5 17β-hydroxysteroid dehydrogenase/ prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact 2009;178:221-7.
181. Sam KM, Labrie F, Poirier D. N-Butyl-N-methyl-11-(3′-hydroxy- 21′,17′-carbolactone-19′-nor-17′α-pregna-1′, 3′,5′(10′)-trien-7′α-yl)-undecanamide:an inhibitor of type 2 17β-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur J Med Chem 2000;35:217-25. (Pubitemid 30165685)
182. Bydal P, Auger S, Poirier D. Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring:structure-activity relationships. Steroids 2004;69:325-42. (Pubitemid 38803000)
183. Tremblay MR, Luu-The V, Leblanc G, Noël P, Breton E, Labrie F et al. Spironolactone-related inhibitors of type II 17β-hydroxysteroid dehydrogenase:chemical synthesis, receptor binding affinities, and proliferative/anti-proliferative activities. Bioorg Med Chem 1999;7:1013-23.
184. Poirier D, Bydal P, Tremblay MR, Sam K-M, Luu-The V. Inhibitors of type II 17β-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 2001;171:119-28.
185. Bagi CM, Wood J, Wilkie D, Dixon B. Effect of 17β-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys. J Musculoskelet Neuronal Interact 2008;8:267-80.
186. Wood J, Bagi CM, Akuche C, Bacchiocchi A, Baryza J, Blue ML et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17β-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorg Med Chem Lett 2006;16:4965-8.
187. Kristofiková Z, Bocková M, Hegnerová K, Bartos A, Klaschka J, Rícny J et al. Enhanced levels of mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 in patients with Alzheimer disease and multiple sclerosis. Mol Biosyst 2009;5:1174-9.
188. Kissinger CR, Rejto PA, Pelletier LA, Thomson JA, Showalter RE, Abreo MA et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor:Implications for design of Alzheimer's disease therapeutics. J Mol Biol 2004;342:943-52.
189. Yang SY, He XY, Schulz H. 3-Hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA dehydrogenase in human health and disease. FEBS J 2005;272:4874-83. (Pubitemid 41415112)
190. He XY, Yang YZ, Peehl DM, Lauderdale A, Schulz H, Yang SY. Oxidative 3-hydroxysteroid dehydrogenase activity of human type 10 17β-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 2003;87:191-8. (Pubitemid 37532526)